“…DM type 2, Mets, hyperlipidemia) that must be treated with other drugs (polypharmacy), which can complicate treatment [20,27] or present favorable effects on psoriasis severity [27,28]. Indeed, several hypoglycemic agents used in the treatment of DM type 2, including metformin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and thiazolidinediones, display simultaneous favorable glycemic and anti-psoriatic effects through targeting skin inflammation networks and keratinocyte proliferation [28]. Moreover, statins, particularly simvastatin and atorvastatin, which are commonly used to lower serum cholesterol and CVD risk, may decrease psoriasis severity due to their effects on lipid metabolism as well as their immunomodulatory and anti-inflammatory actions [20,27].…”